Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in …

…, EA Tokarskaya, DA Egorova, MM Shmarov… - The Lancet, 2021 - thelancet.com
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac
(Sputnik V), showed a good safety profile and induced strong humoral and cellular immune …

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 …

…, NL Lubenets, DA Egorova, MM Shmarov… - The Lancet, 2020 - thelancet.com
Background We developed a heterologous COVID-19 vaccine consisting of two components,
a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (…

[HTML][HTML] An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus …

…, EA Tokarskaya, MM Shmarov… - The Lancet Regional …, 2021 - thelancet.com
Background While the world is experiencing another wave of COVID-19 pandemic, global
vaccination program is hampered by an evident shortage in the supply of licensed vaccines. …

One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the …

…, AS Semikhin, EA Tokarskaya, MM Shmarov… - medRxiv, 2021 - medrxiv.org
Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most
vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, …

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

…, AE Siniavin, EI Burtseva, MM Shmarov… - Frontiers in …, 2024 - frontiersin.org
Seasonal influenza remains a serious global health problem, leading to high mortality rates
among the elderly and individuals with comorbidities. Vaccination is generally accepted as …

[HTML][HTML] New therapy for spinal cord injury: Autologous genetically-enriched leucoconcentrate integrated with epidural electrical stimulation

…, F Fadeev, V Markosyan, M Sokolov, M Shmarov… - Cells, 2022 - mdpi.com
The contemporary strategy for spinal cord injury (SCI) therapy aims to combine multiple
approaches to control pathogenic mechanisms of neurodegeneration and stimulate …

Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

T Povysheva, M Shmarov, D Logunov… - … of Neurosurgery: SPINE, 2017 - thejns.org
OBJECTIVE The most actively explored therapeutic strategy for overcoming spinal cord injury
(SCI) is the delivery of genes encoding molecules that stimulate regeneration. In a mouse …

An open, non-randomised, 1/2 phase study on the safety, tolerability, and immunogenicity of single dose'Sputnik light'vaccine for prevention of coronavirus infection in …

…, YV Simakova, EA Tokarskaya, MM Shmarov… - 2021 - papers.ssrn.com
Background: While the world is experiencing another wave of COVID-19 pandemic, global
vaccination program is hampered by obvious shortage in supply of licensed vaccines. …

[HTML][HTML] Mutations in the genome of avian influenza viruses of the H1 and H5 subtypes responsible for adaptation to mammals

…, DN Shcherbinin, AA Shilov, MM Shmarov… - Microbiology …, 2021 - cyberleninka.ru
Avian influenza viruses of the H1 and H5 subtypes were involved in the formation of highly
pathogenic viruses that caused pandemics and panzootics in the 20th–21st centuries. In …

[HTML][HTML] Molecular and cellular changes in the post-traumatic spinal cord remodeling after autoinfusion of a genetically-enriched leucoconcentrate in a mini-pig model

…, AA Lysenko, IL Tutykhina, MM Shmarov… - Neural Regeneration …, 2023 - journals.lww.com
Post-traumatic spinal cord remodeling includes both degenerating and regenerating processes,
which affect the potency of the functional recovery after spinal cord injury (SCI). Gene …